Drug Trial Radar · NCT04003155
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
527
Actual
Start
Jul 11, 2019
Primary completion
Oct 29, 2020
Study completion Aug 11, 2021
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looks like medicine but did not had any medicine in it.) The study compared fezolinetant and placebo after 4 and 12 weeks of dosing. The study evaluated if fezolinetant reduces the number of hot flashes. And the study evaluated if fezolinetant reduces the severity of the hot flashes. Women in the study received an electronic handheld device at the first study visit. (It was similar to a smart phone.) Each day of the study, study participants used this to record their hot flashes. Their record for the 10 days before the start of study treatment was checked. They remained in the study if their record shown 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they were picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It was like flipping a coin. The study participants took study treatment for 52 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors did not knew who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo) during that time. The last 40 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors knew which study treatment that study participant took during that time. Women who took fezolinetant during the first 12 weeks continued to take the same dose. Women who took placebo during the first 12 weeks took fezolinetant. Their dose was either 30 mg or 45 mg fezolinetant. At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants visited the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine was collected for laboratory tests. Study participants completed questionnaires that were about how hot flashes affect their daily life. Study participants who still had their uterus had the following 2 tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test is transvaginal ultrasound. This test used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had it done at the last study visit if they are due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic was 3 weeks after the last dose of study treatment.
Conditions
- Hot Flashes
Interventions
fezolinetantDrug
Oral Tablet
placeboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
- Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
- Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
- Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
Locations
96 sites in 7 countries. Site status is shown where the registry gives one.
SEC Clinical Research
Andalusia, Alabama
Central Research Associates
Birmingham, Alabama
Achieve Clinical Research, LLC
Ensley, Alabama
Elite Clinical Studies, LLC
Phoenix, Arizona
Eclipse Clinical Research
Tucson, Arizona
Advanced Clinical Research - Rancho Paseo
Banning, California
Hope Clinical Research, LLC
Canoga Park, California
Alliance Research Inc
Canoga Park, California
Marvel Clinical Research
Huntington Beach, California
Grossmont Center for Clinical Research
La Mesa, California
National Research Institute - Panorama
Los Angeles, California
Northern California Research
Sacramento, California
Precision Research Institute, Inc
San Diego, California
Coastal Connecticut Research, LLC
New London, Connecticut
Emerson Clinical Research Institute
Washington D.C., District of Columbia
Precision Clinical Research
Coral Springs, Florida
American Research Institute, Inc.
Cutler Bay, Florida
Avail Clinical Research, LLC
DeLand, Florida
Universal Axon Clinical Research
Doral, Florida
Fleming Island Center for Clinical Research
Fleming Island, Florida
Clinical Physiology Associates
Fort Myers, Florida
Vital Pharma Research Inc.
Hialeah, Florida
Health Awareness
Jupiter, Florida
GYN Research Center
Kissimmee, Florida
Multi-Specialty Research Associates, Inc.
Lake City, Florida
Altus Research
Lake Worth, Florida
Medical Research Center of Miami II
Miami, Florida
Spotlight research center
Miami, Florida
New Age Medical Research Corporation
Miami, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Cornerstone Research Institute
Orlando, Florida
St. Johns Center for Clinical Research
Ponte Vedra, Florida
Health Awareness
Port Saint Lucie, Florida
International Clinical Research
Sanford, Florida
Premier Medical Associates
The Villages, Florida
Better Health Greater Life
Atlanta, Georgia
Gwinnett Research Institute
Buford, Georgia
IACT Health
Columbus, Georgia
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.